Inactive Instrument

Constellation Pharmaceuticals, Inc.

CNST

US2103731061

Biotechnology & Medical Research

Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 3000 Growth Index

June 25, 2021 at 05:00 am

Latest news about Constellation Pharmaceuticals, Inc.

MorphoSys Out Licenses Pre-Clinical Oncology Program	06/12/22	CI
MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	16/07/21	MT
Sector Update: Health Care Stocks Lower Just Ahead of Closing Bell	15/07/21	MT
Sector Update: Health Care Stocks Lacking Much Traction	15/07/21	MT
Constellation Announces Management Changes	15/07/21	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	15/07/21	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	15/07/21	CI
DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	15/07/21	MT
Sector Update: Health Care Stocks Flat To Lower Pre-Bell Thursday	15/07/21	MT
MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	15/07/21	MT
MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	15/07/21	MT
Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	15/07/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	15/07/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	15/07/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	15/07/21	CI
MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	14/07/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from NASDAQ Biotechnology Index	14/07/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2000 Growth Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2000 Value Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell Small Cap Comp Growth Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2500 Value Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 3000 Growth Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000 Value Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2500 Growth Index	25/06/21	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000E Value Index	25/06/21	CI

Chart Constellation Pharmaceuticals, Inc.

Duration

Period

Chart Constellation Pharmaceuticals, Inc.

More charts

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.80%	121B
REGENERON PHARMACEUTICALS, INC.	+19.74%	113B
ARGENX SE	+17.47%	26.02B
BIONTECH SE	-24.93%	19.39B
GENMAB A/S	-19.51%	15.91B
BEIGENE, LTD.	-17.89%	15.09B
WUXI APPTEC CO., LTD.	-46.87%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.63%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+5.65%	13.85B

Bio Therapeutic Drugs